Document Detail


Application of recombinant human erythropoietin in patients with polycystic kidney disease and chronic renal failure.
MedLine Citation:
PMID:  1339766     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recombinant erythropoietin was used in the treatment of the anemic syndrome in 5 patients (4 women and 1 man), aged 45-63, with confirmed autosomal dominant polycystic kidney disease. All patients were with II stage chronic renal insufficiency. The treatment was conducted with Eprex (Silag, Switzerland) administered subcutaneously in a dose of 50 U/kg of body weight for three months. Once weekly, hemoglobin, hematocrit, erythrocytes, and serum iron were investigated in all patients. Simultaneously, we used recombinant erythropoietin in the same dose and treatment protocol on a control group of 3 women and 2 men with II stage chronic renal insufficiency but without polycystic kidney disease. The control patients were suffering from other diseases leading to uremia. In both groups, the hemoglobin and hematocrit were found to be significantly increased whereas their serum iron tended to decrease which required inclusion of iron containing preparations in the treatment. We found no significant differences both in the dynamics of influencing the disease and in the final results of the treatment with erythropoietin between the patients with polycystic kidney diseases and those without polycystosis and chronic renal insufficiency. No allergic reactions were observed during treatment. Arterial pressure was elevated in all patients. We think that recombinant erythropoietin can be used successfully in the treatment of renal anemia in patients with polycystic kidney disease and chronic renal insufficiency in the predialysis stage.
Authors:
D Dimitrakov; E Kunchev
Related Documents :
16595066 - Erythropoietin and neuroprotection: a therapeutic perspective.
12588566 - Medical and functional consequences of anemia in the elderly.
3135496 - Aplastic anemia complicating orthotopic liver transplantation for non-a, non-b hepatitis.
3893396 - Erythroid progenitor growth in erythrocytosic transplanted patients.
9763556 - Efficacy and costs of granulocyte colony-stimulating factor in allogeneic t-cell deplet...
14605036 - Lung transplantation exacerbates gastroesophageal reflux disease.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Folia medica     Volume:  34     ISSN:  0204-8043     ISO Abbreviation:  Folia Med (Plovdiv)     Publication Date:  1992  
Date Detail:
Created Date:  1993-11-19     Completed Date:  1993-11-19     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  2984761R     Medline TA:  Folia Med (Plovdiv)     Country:  BULGARIA    
Other Details:
Languages:  eng     Pagination:  41-4     Citation Subset:  IM    
Affiliation:
University of Medicine, Clinic of Nephrology, Plovdiv, Bulgaria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia / blood,  drug therapy
Erythropoietin / therapeutic use*
Female
Humans
Kidney Failure, Chronic / drug therapy*
Male
Middle Aged
Polycystic Kidney, Autosomal Dominant / drug therapy*
Recombinant Proteins / therapeutic use
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Digital subtraction angiopulmography in children.
Next Document:  Motor cortex transcranial magnetic stimulation topography assessed by distribution and size of evoke...